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Magnetic resonance imaging 
for assessment of cerebrovascular reactivity 
and its relationship to cognition: a systematic 
review
Sarah J. Catchlove1* , Andrew Pipingas1, Matthew E. Hughes2,3 and Helen Macpherson4
Abstract 
Background: Cerebrovascular reactivity (CVR) refers to the responsiveness of cerebral vasculature to vasoactive stim-
uli. CVR is an indicator of brain health and can be assessed using vasodilatory techniques and magnetic resonance 
imaging (MRI). Using such approaches, some researchers have explored the relationship between CVR and cognition; 
here we systematically review this work.
Results: We extracted information pertaining to: (1) study location and design, participant characteristics, sam-
ple sizes, (2) design of vascular challenge, end-tidal  CO2  (etCO2) concentrations (if applicable), (3) MRI protocol, (4) 
cognitive assessment, (5) CVR values, and outcomes of statistical analyses with cognitive tests. Five studies assessed 
participants with cognitive impairment compared to controls, one studied patients with multiple sclerosis with or 
without cognitive impairment compared to controls, one examined patients with moyamoya disease with or without 
cognitive impairment, two investigated patients with Type 2 diabetes mellitus (T2DM), and one was a cross-sectional 
study with younger and older healthy adults. Cognition was typically probed using the MMSE and tests of executive 
function, while a number of vasodilatory techniques were employed.
Conclusion: CVR was associated with cognition in six of ten studies, but heterogeneity of study samples, designs and 
vasodilatory methods may have a role in the inconsistent findings. We make recommendations for future research 
that includes use of a multi-domain cognitive assessment and standardised hypercapnic challenge with MRI.
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Background
Rising life expectancies, together with declining fertil-
ity rates, is leading to rapid global ageing. It is estimated 
that by the year 2050 the proportion of people aged 
over 60 years will double from approximately 11 to 22% 
worldwide [1]. As the population ages, the number of 
older adults living with impaired cognition and demen-
tia continues to increase. While a variety of mechanisms 
are thought to contribute to the genesis of cognitive 
impairment, there is emerging evidence that the signaling 
between various elements of the neurovascular unit 
becomes dysfunctional with increasing age, leading to 
neurovascular uncoupling and dysregulation of cerebral 
blood flow (CBF) in response to neuronal and metabolic 
demands [2, 3]. Cerebrovascular reactivity (CVR) refers 
to the response of cerebral blood vessels to vasoactive 
stimuli. Dysfunctional CVR impairs blood delivery to 
brain regions requiring supply, which both precedes and 
contributes to neuropathology over time. Impaired CVR 
has been implicated in a wide range of disorders includ-
ing stroke [4–6], multiple sclerosis [7], hypertension [8], 
diabetes [9, 10], cardiovascular disease [11] and dementia 
[12–15]. Further, diminished reactivity has been found to 
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contribute to mild cognitive impairment in the non-clini-
cal general population [16].
This potential link between CVR and cognitive impair-
ment is interesting as it suggests that optimal functioning 
of the cerebral circulatory system is important for main-
taining cognitive functions. The relationship between 
cognitive decline and numerous vascular anomalies, 
including stiffness of the peripheral arteries and aorta 
[17, 18], hypoperfusion [19, 20], cerebrovascular disease 
[21], and pathology of the carotid arteries [22, 23] has 
been well established in the literature. To date however, 
the relationship between CVR and cognitive functions 
has been poorly understood.
CVR is generally measured as a change in some index of 
blood flow (e.g., blood flow velocity measured with ultra-
sound or blood oxygen level dependent (BOLD) signal 
change measured with fMRI) in response to a vasoactive 
stimulus. Hypercapnia (increased blood carbon dioxide 
 (CO2) concentration) is the most often used stimulus to 
elicit increased blood flow via vasodilation. Hypercap-
nia can be induced in several ways including inhalation 
of  CO2-enriched air, breath-holding, and rebreathing. 
While there are numerous vasoactive challenges that can 
elicit a change in blood flow required for the assessment 
of CVR, inhalation of  CO2-enriched air is most suitable 
due to the practicality of its use and the ease with which 
it can be standardized [24]. Acetazolamide, a carbonic 
anhydrase inhibitor, has the same capacity to dilate the 
cerebral microvasculature via increasing carbonic acid in 
the arterial blood, and is often used to elicit vasodilation 
in studies of CVR [25, 26].
Likewise, various tools can be employed to measure the 
change in blood flow. Most frequently used is the tran-
scranial Doppler ultrasound (TCD). This method is inex-
pensive, easy to use, non-invasive, is viable for use with 
large cerebral vessels and has high temporal resolution. 
However, TCD has low spatial resolution; hence precise 
regional investigations cannot be performed. Single-pho-
ton emission computed tomography (SPECT), positron 
emission tomography (PET) and other computed tomog-
raphy (CT)-based technologies also exhibit poor spatial 
resolution, but are further complicated by the necessity 
of exposing participants to ionizing radiation. Advances 
with MRI-based imaging have overcome these limitations 
whereby CVR assessments can be performed without the 
use of exogenous contrast agents, and with high spatial 
resolution so that the responsiveness of blood vessels 
within discrete brain areas may be studied independently.
Research investigating the relationship between vascu-
lar reactivity and cognitive performance has commonly 
used CT or TCD technology, demonstrating reduced 
CVR in cognitively impaired patients [12, 14, 27, 28]. 
Studies using TCD have shown significant relationships 
between CVR and cognitive status assessed with the 
mini-mental state examination (MMSE) [28], and with 
tests of executive function, attention and memory [29]. 
However, the lack of regional specificity of TCD does 
not enable an examination of region-specific relation-
ships between CVR and cognitive abilities. To address 
this apparent gap in the literature, the current work aims 
to systematically review all research articles investigating 
the association between cognitive performance and cer-
ebrovascular reactivity to a vasoactive stimulus measured 
using MRI.
Methods
Search criteria
Searches were conducted using Pubmed and Scopus 
from earliest record until 15th July 2017. Search terms 
were entered as follows: Pubmed (cognition OR cogni-
tive OR memory OR attention) AND (“cerebral vascular 
reactivity” OR “cerebrovascular reactivity” OR “cerebral 
vasoreactivity” OR cvr OR “cerebral vasomotor reactiv-
ity” OR “vasomotor responsiveness” OR “cerebrovascu-
lar responsiveness”) AND (Humans [Mesh]); and Scopus 
(TITLE-ABS-KEY (cognition OR cognitive OR memory 
OR attention) AND TITLE-ABS-KEY (“cerebral vascular 
reactivity” OR “cerebrovascular reactivity” OR “cerebral 
vasoreactivity” OR cvr OR “cerebral vasomotor reactiv-
ity” OR “vasomotor responsiveness” OR “cerebrovascular 
responsiveness”)) AND (LIMIT-TO (DOCTYPE, “ar”)).
Only studies published in English using MRI-based 
CVR assessments and conducted with adult (> 18 years) 
humans were included. Exclusion criteria included ani-
mal studies, CVR assessed with imaging modalities other 
than MRI, not performing a cognitive/neuropsychologi-
cal assessment, or not analysing the associations between 
CVR and cognition. The reference lists of the included 
studies were also searched.
Quality assessment and extracted information
Studies deemed eligible were checked for quality using 
the NIH Quality Assessment Tool for Case/Control Stud-
ies and the Tool for Observational Cohort and Cross-
Sectional Studies and the PRISMA (Preferred Reporting 
Items for Systematic reviews and Meta-Analyses) guide-
lines. Information extracted from the studies related 
to the country, year of publication, MRI technique and 
analysis, vasodilatory challenge, CVR values, cognitive/
neuropsychological assessment, and participant demo-
graphics including age, gender, years of education, cog-
nitive profile and other health status information where 
available.
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Results
10 studies were included in the final review [10, 13, 
14, 30–36]. All studies were of a fair to good quality as 
assessed by two independent researchers (SC and HM; 
See Fig. 1). 
Study demographics and details
Research was conducted in four countries (USA n = 4, 
Canada n = 2, Switzerland n = 1, France n = 3). Partici-
pants in 7 of the studies had an average age of mid-to-
late 60’s to early 70’s [10, 13, 30–32, 35, 37], one study 
investigated adults aged 30–50 years (patients mean age 
39 ± 5.91 years, controls mean age 41 ± 6.38 years) [36], 
one study recruited adults with moyamoya disease aged 
over 18  years (range 29–73, mean age 40.4  years) [34], 
while the remaining study involved a cohort of older 
(mean age 63 ± 5  years) and younger adults (mean age 
24 ± 3 years) [33].
Two studies investigated the differences in CVR and 
cognition between patients with type 2 diabetes mellitus 
(T2DM) versus healthy controls [10, 32]. Metzger et  al. 
[36] assessed cerebral vasoreactivity and cognitive sta-
tus in multiple sclerosis patients versus healthy controls. 
Two studies included patient samples with mild cognitive 
impairment (MCI) and Alzheimer’s disease (AD) matched 
with healthy controls [13, 31], while two examined only 
MCI and healthy controls [35, 37] and one paper exam-
ined only AD versus healthy controls [30]. Calviere et al. 
[34] investigated CVR and cognitive impairment in 
patients with moyamoya disease. The work by Gauthier 
et al. [33] was a cross-sectional study assessing differences 
between groups of healthy younger and older adults.
Fig. 1 Flowchart of study selection
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All studies were single-visit examinations, with the 
exception of Chung et  al. [32] which was longitudinal; 
participants were assessed at baseline and 2-year follow-
up. Table 1 displays patient characteristics.
Vascular challenge paradigm
Vascular challenges varied between studies. Five elic-
ited hypercapnia via fixed-level  CO2-enriched gas 
inhalation. Concentrations varied between 5%  CO2 in 
medical air [30, 35], 7%  CO2 in medical air [31], 7%  CO2 
in 93% oxygen (carbogen) [13] and 8%  CO2-enriched 
gas  (BACTAL®) [36]. Two studies used  CO2 rebreath-
ing as the hypercapnic manipulation, though both failed 
to report the length of the rebreathing period, and the 
size of the reservoir used [32, 37]. Tchistiakova et al. [10] 
used the breath-hold technique, wherein participants 
performed a series of 6 × 15 s breath holds following 3 s 
of exhalation with 30  s of intermittent regular breath-
ing. Gauthier et al. [33] used a computer-controlled gas 
delivery system which prospectively targeted the partial 
pressure of expired  CO2  (etCO2) to 40  mmHg for nor-
mocapnia, and 45  mmHg for the hypercapnia period, 
whilst maintaining the expired  O2  (etO2) at 100  mmHg 
throughout the procedure. The duration of gas delivery 
also varied across these studies, see Table  2 for details. 
The remaining study elicited vasodilation via injection of 
15 mg/kg acetazolamide [34].
Cognitive/neuropsychological assessment
While the majority of the studies reported more than one 
cognitive assessment, we were primarily interested in 
the tests that were analysed in connection with CVR. All 
but three studies [10, 34, 36] reported mini-mental state 
examination (MMSE) [38] scores. Of the seven studies 
that reported MMSE, four investigated the relationship 
between CVR and MMSE score [13, 30, 31, 37]. Results 
are reviewed in the discussion section.
Assessments of executive function in connection with 
CVR were included in five studies. Chung et  al. [32] 
composed a composite measure of the average of verbal 
fluency and Trail Making Tests A & B scores, Gauthier 
et al. [33] used a modified Stroop task to measure execu-
tive function, and Tchistiakova et  al. [10] employed the 
Wisconsin Card Sorting test (WCST). Calviere et  al. 
[34] used a battery of tests examining executive func-
tion (letter and category fluency tests, Trail Making Test 
B, Stroop interference, Brixton test and a modified ver-
sion of the WSCT that included both number of catego-
ries and number of preservations), and attention (Trail 
Making Test A, and colored dots and words of the Stroop 
test) to categorize patients as being cognitively impaired 
or not. Patients scoring below  5th percentile of the nor-
mative mean on 3 or more subtests were considered to 
have dysexecutive cognitive syndrome (DCS), which 
defined the cognitively impaired sample in this cohort. 
Metzger et  al. [36] used a similar battery, the BCcog-
SEP [39] designed to evaluate cognitive impairment in 
multiple sclerosis. Tasks included assessments of verbal 
short-term memory, visual perception, digit spans, work-
ing memory, processing speed, go-no-go test and verbal 
fluency. Cognitive status was defined by this evaluation, 
patients were classified as cognitively impaired if they 
scored below the  5th percentile of the normative mean of 
the BCCOG SEP on at least 4 subtests. Other cognitive 
tasks that did not overlap between studies are outlined in 
Table 1.
MRI data acquisition
BOLD fMRI was used in six of the studies [10, 13, 30, 31, 
35, 36]. Three papers employed the arterial spin labeling 
(ASL) MRI technique to measure changes in brain per-
fusion. Of these, one used pulsed ASL (PASL) [37], one 
used continuous ASL (CASL) [32] and the final employed 
pseudo-continuous ASL (pCASL) [33]. However, in the 
work of Gauthier et al. the images acquired with pCASL 
sequence were separated into BOLD and CBF time-series 
data, of which only the BOLD information was used in 
CVR analysis. Therefore, this work is considered to be a 
BOLD imaging study. The remaining study used dynamic 
susceptibility contrast-enhanced (DSC) MRI [34]. All but 
two studies [13, 34] used an MR scanner with magnetic 
field strength of 3T. MR protocol information is displayed 
in Table 2.
Summary of regional CVR findings
The studies that employed BOLD imaging assessed CVR 
in various regions-of-interest (ROIs) with some contrast-
ing findings. Results are shown in Table 2. Cantin et  al. 
[13] observed regional impairment in CVR between 
healthy controls and patients with cognitive impairment, 
particularly in posterior brain areas, whereas Yezhuvath 
et al. [30] reported CVR deficits in more rostral regions 
in patients with AD compared to healthy controls. Can-
tin et al. [13] investigated CVR in several regions: frontal, 
parietal, temporal and occipital lobes, the cingulum, the 
insula, the striatum and the thalamus. Yezhuvath et  al. 
performed a voxel-wise regression and region-of-interest 
(ROI) analysis using 6 regions: the occipital lobe, tem-
poral lobe, frontal lobe, parietal lobe, insular cortex and 
subcortical grey matter. This is in contrast to the work by 
Thomas et al. [35], who found no differences in reactivity 
between adults with amnestic mild cognitive impairment 
compared to controls using a voxel-wise comparison of 
whole-brain grey matter CVR maps. Metzger et  al. [36] 
calculated CVR in 8 regions of interest (ROIs): occipital, 
parietal, temporal frontal, insula, cingulum, thalamus 
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and striatum, as well as a global median. CVR in all ROIs 
was significantly reduced in MS patients with cognitive 
impairment compared to those who were not cognitively 
impaired.
Another study [31] analysed the BOLD data at the level 
of overall CVR effect, differences between lobes (7 lobes 
were delineated as per previous work), brain regions (88 
cortical and subcortical regions included), and finally 
the associations between CVR velocity and the cognitive 
assessment scores. CVR velocity refers to the temporal 
dynamics of the CVR response, representing the rate of 
the vasodilation. It was observed that the largest differ-
ences in CVR between AD and healthy controls were 
seen in the frontal and occipital lobes.
Calviere et  al. [34] used 22 ROIs manually drawn on 
the bilateral frontal and temporoparietal areas of the cer-
ebral cortex, and reference areas in the cerebellum. The 
mean transit time (MTT) and cerebral blood volume 
(CBV) values from each area were estimated from per-
fusion weighted image analysis, and averaged to give one 
measure from each region. Ratios of CBV in the frontal 
and temporoparietal areas were calculated relative to the 
cerebellar CBV, which was used as a control region. The 
CVR values for each region were estimated from the CBV 
values relative to the cerebellum. Frontal CVR was lower 
in cognitively impaired patients with moyamoya disease 
than those without cognitive impairment.
Gauthier et al. examined CVR using a pseudo-contin-
uous ASL (pcASL) sequence. BOLD data was acquired 
and intersected with areas of significant signal change in 
response to the vasoactive stimulus observed with ASL 
data using cluster analysis to define one frontal ROI [33]. 
This region was found to be slightly lower in reactivity in 
older adults compared to younger, yet this difference was 
not significant, nor was CVR in this region associated 
with cognitive function.
Chung et al. [32] investigated CVR in the frontal, tem-
poral, parietal, occipital and insula lobes of the brain, as 
well as calculating a global CVR index. The frontal and 
parietal lobes were associated with change in execu-
tive function in patients with T2DM, but not in healthy 
controls.
Tchistiakova et  al. [10] performed a functional ROI 
analysis, and reported that there was reduced CVR in 
several regionals in those with both hypertension and 
T2DM compared to hypertension alone in the left hemi-
sphere (pericalcarine cortex), right hemisphere (inferior 
parietal, lateral occipital and precuneus) and the cuneus, 
lingual gyri and superior parietal lobes bilaterally.
CVR and neuroimaging correlates of cognitive dysfunction
Seven studies explicitly mentioned correcting for par-
tial volume effects, grey matter atrophy or white matter 
hyper-intensities (WMH) in their image analyses [10, 13, 
30, 31, 33, 36, 37]. In one remaining paper the authors 
made mention of normalising the perfusion signal for tis-
sue volume, yet did not give further information on the 
specifics of this procedure [32].
Several studies examined the relationship of CVR 
to WMH, with some mixed results. Gauthier et  al. [33] 
showed that age, gender and volume of WMH accounted 
for a significant amount of variance in frontal CVR. Simi-
larly, Yezhuvath et  al. [30] found that lower CVR was 
associated with greater volume of WMH in their cohort 
of AD and healthy controls. Yet another study investigat-
ing the association of grey matter CVR, cardiovascular 
risk factors and periventricular WMH found that these 
parameters were intercorrelated [37]. In contrast, Rich-
iardi et  al. [31] reported that there was no significant 
association between severity of WMH and CVR velocity 
in their cohort of AD, aMCI and healthy controls. Simi-
larly Metzger et al. [36] found that there was no associa-
tion between CVR and WMH in MS patients, healthy 
controls or the cohort as a whole.
Of the reviewed papers, only one investigated hip-
pocampal atrophy in relation to reactivity, and it was 
found to negatively correlate with CVR in the occipital, 
parietal, striatum and temporal ROIs [13].
Calculation of CVR
Metzger et al. [36] did not monitor end tidal-CO2  (etCO2) 
throughout their experiments, thus they were unable to 
use this trace as a regressor in their modelling of CVR. 
This study used mean  etCO2 obtained from a standard 
population as a regressor in their general linear model 
(GLM). Richiardi et al. [31] did not monitor  etCO2 either. 
In this work two  CO2 regression coefficients were calcu-
lated analytically to reflect the CVR amplitude and veloc-
ity separately, though the authors only report velocity in 
this paper. These regression coefficients were calculated 
from mathematical models of nominal and slow  etCO2 
responses to a  CO2 challenge, to represent the expected 
responses in healthy subjects and those with slower ves-
sel dilation respectively. CVR velocity was defined in this 
paper as the rate of vasodilation. While the method of 
CVR estimation here is acceptable, the unavailability of 
 etCO2 data potentially limits the strength of these find-
ings. Similarly, Tchistiakova et  al. [10] did not record 
 etCO2 throughout the hypercapnic procedure. These 
researchers calculated CVR as the % change in BOLD 
signal during 6 × 15 s breath-holds.
Calviere et  al. [34] used the regional cerebral blood 
volume (rCBV) ratio from the regions of interest (ROIs) 
that was relative to the CBV of the cerebellum (control 
region). No  etCO2 was recorded in this study as vasodila-
tion was elicited via injection of acetazolamide, thus the 
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calculation used in this study was: CVR = ([rCBV ratio 
before acetazolamide − rCBV ratio after acetazolamide]/
rCBV ratio before acetazolamide) × 100.
Chung [32] used a rebreathing paradigm to assess vaso-
dilation, vasoconstriction and vasoreactivity separately. 
Vasodilation was measured as the perfusion increase 
from baseline during  CO2 rebreathing normalised to the 
change in  etCO2 between baseline and rebreathing. Vaso-
reactivity was defined as the best-fitting slope between 
normal breathing, vasodilation and vasoconstriction. It 
should be noted that the ‘gold standard’ for CVR meas-
urement is more likely the whole vasodilatory range of 
hypocapnia (elicited by hyperventilation) to hypercap-
nia [40]. However, CVR is most commonly calculated 
as the difference in CBF (or surrogate) between baseline 
and during a vascular challenge divided by the change in 
 etCO2 between these conditions, thus the vasodilation 
measure is taken as CVR, not the vasoreactivity measure 
in this instance.
The remainder of the studies estimated CVR using the 
standard calculation:
where  MRIparameterdil is the CBF or BOLD signal meas-
ured during the vasodilated period;  MRIparameterrest 
indicates the CBF or BOLD signal measured at baseline; 
and ΔetCO2 is the difference is end-tidal  CO2 in mmHg 
between the two conditions.
Relationship between CVR and cognition
Of the four papers that analysed the association of CVR 
to MMSE score, two reported significant positive correla-
tions [13, 31], and two reported no relationship [30, 37]. 
Metzger’s work found that CVR was lower in MS patients 
with cognitive impairment compared to non-impaired 
patients [36], supporting the findings of Calviere et  al. 
[34], who reported that CVR was significantly reduced in 
patients with moyamoya disease and dysexecutive cogni-
tive syndrome (DCS) compared to patients without DCS. 
This is in contrast to the results of Thomas’s study, which 
concluded that whole-brain grey matter CVR was not 
significantly different between MCI and healthy control 
groups [35].
Tchistiakova et al.’s [10] research involved three meas-
ures of cognitive function, none of which were found 
to correlate with CVR. These measures were tests of 
memory, processing speed and executive function. A 
second study [33] also reported no significant associa-
tion between executive function as measured by a Stroop 
task, yet the work by Chung et  al. [32] found that CVR 
decline was linked to a decrease in executive function in 
CVR =(
(
MRIparameterdil−MRIparameterrest
)
/
MRIparameterrest)× 100/�etCO2
T2DM at 2-year follow-up. These results are further dis-
cussed below.
Discussion
This paper systematically reviewed research articles that 
examined the association between cognition and cer-
ebrovascular reactivity (CVR) using MRI. Six out of ten 
studies described significant relationships between CVR 
and cognition, including a longitudinal study which 
reported that lower CVR was predictive of cognitive 
decline over a 2-year period. The association of CVR to 
cognition is more established in individuals with cogni-
tive dysfunctions, while this link is less well-known in 
cognitively normal adults. There was an over-reliance on 
imprecise measures of cognition, and the vascular chal-
lenges used to measure CVR varied widely.
CVR is reduced in adults with cognitive dysfunction
CVR was consistently lower in cognitively impaired 
adults versus healthy controls, or patients without cog-
nitive impairment in the reviewed research (6 of 10 
studies). Two studies reported significant correlations 
between cognition measured by MMSE and CVR in 
multiple brain regions [13, 31]. These investigations also 
observed that CVR was significantly reduced in AD and 
MCI patients, and that AD patients had significantly 
slower responses to hypercapnia (i.e. CVR velocity was 
reduced), compared to healthy controls. In contrast, 
Glodzik et  al. and Yezhuvath et  al. [30, 37] reported 
that CVR was not directly related to cognition meas-
ured using the MMSE. However, in both of these studies 
patients with cognitive impairment had lower reactivity 
than matched healthy controls, seen in the hippocam-
pus in Glodzik et al. [37] and in the prefrontal, anterior 
cingulate and insular cortices in the study by Yezhuvath 
et al. [30]. Two other studies reported that CVR was sig-
nificantly reduced in participants with cognitive impair-
ment compared to those who were cognitively normal 
[34, 36].
These findings are supported by evidence using other 
modalities linking dementia severity with cerebrovas-
cular responsiveness [27, 28]. Transcranial Doppler 
(TCD) ultrasound is often used to measure changes in 
CBF velocity in investigations of CVR. This method, 
while temporally precise, lacks spatial resolution, thus 
its practicality in regional CVR examinations is limited. 
Nonetheless, research conducted into the relationship 
between CVR and cognition with TCD has shown inter-
esting results. Silvestrini et  al. [28] reported that CVR 
as measured using the breath-hold index and TCD was 
the sole predictor of cognitive decline in patients with 
AD. Moreover, breath-hold index has been found to be 
associated with early cognitive impairment [41], as well 
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as an increased risk of conversion from MCI to AD [27]. 
A systematic review of TCD analyses found that CVR to 
hypercapnia was a good differentiator of dementia sub-
types across multiple studies [42]. Overall, the results of 
the reviewed studies lend support to the hypothesis that 
CVR and cognitive functioning are linked, evidenced by 
findings of reduced reactivity in patients with cognitive 
impairment compared to cognitively healthy controls.
While the data reviewed is suggestive of reduced vascu-
lar reactivity in individuals with cognitive impairment, a 
definitive relationship between CVR and cognition in cog-
nitively healthy adults was not identified. Only one study 
focused exclusively on cognitively normal adults without 
chronic health conditions [33], whilst five studies included 
healthy controls as compared to patients with cognition 
impairment, and examined CVR and cognition within 
these participants [13, 30–32, 35]. Two investigations com-
pared patients with cognitive impairment to those with-
out. Metzger studied MS in relation to healthy controls 
[36], whilst Thomas et al. [34] investigated only individu-
als with moyamoya disease (MMD). The remaining study 
investigated CVR and cognition in cognitively normal 
individuals with hypertension with or without co-morbid 
T2DM [10]. Within the reviewed studies, imprecise meth-
ods were used for evaluation of cognitive function and 
CVR. Reliance on the mini-mental state exam (MMSE) 
as the main assessment of cognition in several studies [13, 
30, 31, 37] necessitates some caution, as this measure may 
not be sufficiently sensitive to variation in cognitive capa-
bility, nor does it allow for distinction between different 
cognitive domains [38]. This is evidenced by the findings of 
Richiardi et al. [30] in which no evidence of a relationship 
between CVR and cognitive performance was found using 
measures of global cognitive function, yet a significant cor-
relation was observed with language ability. The MMSE is 
specifically designed as a screening tool for distinguish-
ing between individuals with and without gross cognitive 
impairment [38], and as such its usefulness for precise 
cognitive assessment is not ideal.
Among research that assessed cognitively healthy 
cohorts and those assessing the cognitive capabilities of 
individuals with MS or MMD, tests of executive func-
tion were used. However the specific tests used to define 
this construct varied between the five studies, including 
tasks of inhibitory control, task-switching, verbal fluency, 
and processing speed, among others [10, 32–34, 36] (see 
Table 1 for details). Of the two studies assessing patients 
[34, 36] batteries of neuropsychological tests examin-
ing executive function (amongst others) were used to 
determine cognitive status. While results of two studies 
showed that executive function was not directly corre-
lated with CVR in either frontal cortex [33] or averaged 
across the whole brain [10], the two patient studies both 
reported that CVR was significantly lower in individuals 
with cognitive impairment compared to those without. 
This was observed in the frontal region in MMD [34], 
and in the whole brain grey matter, as well as in a region-
of-interest analysis comprising multiple brain areas in 
MS [36]. Similarly, Chung et al. [32] observed that global 
CVR was positively associated with executive function in 
patients with Type 2 diabetes mellitus (T2DM). In T2DM 
patients, decreased global, frontal and parietal vasodila-
tion at 2-year follow up was linked to accelerated declines 
in executive function. The executive function task was 
composed of separate tasks of verbal fluency and Trail 
Making Task A, which assesses task-switching and visual 
attention. The studies that failed to observe any associa-
tion between CVR and executive function used tasks that 
assessed interference and flexibility in thinking (Stroop 
and the Wisconsin Card Sorting Task, respectively), 
whilst the patient studies that did observe an association 
defined cognitive status on the basis of multiple execu-
tive function tasks. Thus it could be that some aspects of 
executive function are more related to CVR than others. 
Notably, it is thought that there are from 3 to as many as 
7 distinguishable executive abilities [43], hence a more 
comprehensive approach to assessment would be neces-
sary to draw definitive conclusions.
Relationship between CVR and cognition may be mediated 
by cardiovascular risk factors in cognitively healthy adults
There is evidence that CVR is related to executive func-
tion in populations with cardiovascular risk [10, 32]. One 
study [10] reported that CVR was significantly lower in 
those with comorbid hypertension and T2DM versus 
participants with hypertension alone. Similarly, Chung 
et al. [32] reported that higher inflammatory markers in 
T2DM were linked to greater reductions in CVR, which 
resulted in accelerated cognitive decline over a 2-year 
period. Gauthier et  al. [33] reported an association 
between cognitive performance and aortic pulse wave 
velocity (PWV) in their healthy cohort, yet no direct link 
between CVR and cognition was observed. This find-
ing was interpreted as indicating that declining vascular 
health, even in primary stages, negatively impacts cogni-
tion. Due to the above-average health of the cohort only 
minor differences in cerebrovascular properties were 
seen, as compared to larger changes seen in aortic elas-
ticity between younger and older adults. Small blood 
vessel changes, coupled with the known low signal to 
noise ratio (SNR) present in BOLD imaging was posited 
to explain the unexpected lack of relationship observed 
between CVR and cognition in this study.
The relationship between cardiovascular risk and CVR 
was more clearly demonstrated by Glodzik et  al. [37], 
who reported moderate negative correlations between 
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the two in the hippocampus (r = − 0.41) and cortical grey 
matter (r = − 0.46) in both patients and healthy controls. 
Likewise, there is evidence of a link between reduced 
CVR and increased vascular risk in previous studies 
using MRI [44] and TCD [45]. Together, these findings 
may indicate that decreased reactivity may be the result 
of poor vascular health in general, and this is the pri-
mary factor triggering neurocognitive decline. Extensive 
evidence indicates that risk factors for cardiovascular 
disease precede and facilitate cognitive deterioration in 
aging [46–48].
Cardiovascular factors can result in dysfunctional reac-
tivity in specific brain regions, leading to hypoperfusion 
which may pertain to cognitive impairment. The dis-
crepancies between these three studies are multifaceted 
including use of different: executive tasks; methods of 
inducing hypercapnia; and, different imaging techniques 
[10, 32, 33]. These discrepancies’ limit the generalisability 
of the findings to a wider cohort; however, it can be seen 
that there is a possible association between cardiovascu-
lar risk factors and CVR which may mediate the relation-
ship between CVR and executive function in cognitively 
healthy individuals. Further studies are needed to con-
firm these associations.
Similarly, there is the possibility that the observed rela-
tionships between CVR and cognition could be mediated 
by the presence of other cerebral pathologies known to 
disrupt cognition, such as white matter hyper-intensi-
ties (WHM) and hippocampal atrophy. It is understood 
that severity of WMH corresponds to cognitive decline 
[49, 50], and evidence has shown that normal-appearing 
white matter that progresses to WMH has lower CVR 
than areas that do not progress [51]. Within the reviewed 
articles, the relationship of CVR to WMH was mixed, 
with three [30, 33, 37] of five studies reported a signifi-
cant correlation. Interestingly, all three of these papers 
observed significant relationships between cognition and 
CVR, thus it is apparent that continued research investi-
gating these associations is necessary.
Methodological considerations
While the results of the reviewed studies are inconsist-
ent, this is likely influenced by heterogeneous samples, 
imprecise cognitive testing instruments (as outlined 
above), varying procedures for inducing vasodilation and 
differences in imaging protocols.
Differences in vascular challenge
All studies induced an increase in cerebral blood flow; 
however, not all manipulations are equal in their capacity 
to elicit vasodilation. Whilst the breath-hold method is 
used widely, is inexpensive and efficient in inducing CBF 
changes, this technique may produce less reproducible 
stimuli and/or data due to participant compliance, as well 
as individual differences in breath hold capacity. Breath-
hold and re-breathing procedures during MR imaging 
also present potential risk of motion artifacts, which 
may result in undesirable signal differences [52]. It is well 
established that the strength and duration of the stimulus 
effects the cerebrovascular response [53]. Inhalation of 
 CO2-enriched gas mixture has been shown to be a more 
highly reliable means to induce hypercapnia and stimu-
late the cerebral vasculature [54–56].
Prospective targeting of  etCO2 has been deemed the 
most standardisable stimuli for measuring CVR in a 
recent review paper [24], yet only one study included in 
the current work employed this technique [33]. It should 
be noted however, that the literature is far from a consen-
sus on which vascular challenge is most appropriate for 
assessment of CVR.
Five studies used the more traditional method of inha-
lation of fixed-level  CO2-enriched gas. Differences may 
appear somewhat minor—a discrepancy of 2%  CO2 con-
centration between the 7% used by Richiardi et  al. [31] 
and 5% by both Thomas [35] and Yezhuvath et  al. [30]; 
while Richiardi et al. and Cantin et al. [13] used the same 
concentration of  CO2 (7%), the latter study mixed the gas 
with 93%  O2, a substance known as carbogen, rather than 
medical air, which is balanced with  N2. The gas concen-
tration utilised by Metzger [36] was slightly higher again 
(8%  BACTAL®), and it should be noted that the composi-
tion of this gas mixture was unreported, and unable to be 
identified from an internet search.
While these differences in  CO2 concentration may 
seem trivial, the evidence suggests that the relationship 
between BOLD signal and  PaCO2 is non-linear, thus 
CVR results may be dependent on the  CO2 concen-
tration used, as well as baseline  PaCO2 [57]. The use of 
carbogen (and potentially,  BACTAL®) as the vasoactive 
stimulus [13], rather than standard medical air, has impli-
cations for the measurement of CVR, particularly when 
combined with BOLD imaging [54]. The percentage of 
oxygen present in carbogen is greater than that in the 
atmosphere, which will result in an increase in arterial 
partial pressure of  O2  (PaO2), and possible vasoconstric-
tion, confounding the vasodilatory response intended for 
CVR measurement. By nature, BOLD imaging relies on 
the ratio of oxygenated to deoxygenated hemoglobin in 
the blood, and any increase in  PaO2 in the brain will elicit 
unwanted changes in the BOLD signal. BOLD is also 
sensitive to changes in blood flow, volume and oxygen 
metabolism, whilst ASL measures flow only, and is not 
affected by changes in blood oxygenation.
Two studies employed  CO2 rebreathing [32, 37]. Both 
of these papers lacked information regarding the vol-
ume of the respiration reservoirs used and length of 
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rebreathing period in the paradigms, hampering com-
parability. Chung et al. [52] also failed to report the end-
tidal  CO2 values. The speed at which partial pressure of 
 CO2  (PaCO2) rises will be affected by respiration rates 
and the volume of the rebreathing reservoir, ultimately 
influencing the measured CVR value. Likewise, breath-
holding may produce confounding variables, as the rise 
in  PaCO2 during breath-holding varies between individu-
als due to differences in lung size and metabolic rate [24]. 
This method also relies heavily on participant compliance 
and may be difficult or uncomfortable for some to per-
form [58].
An acetazolamide challenge was used in one study [34]. 
Whilst this method is safe, does not rely on subject coop-
eration and is widely used in clinical settings, administra-
tion via injection is invasive, and a standardized dose may 
not produce the replicable stimulus necessary for CVR 
estimation due to individual variability [24]. For the pur-
poses of participant comfort, less invasive stimuli would 
be preferable for measurement of CVR.
There are multiple options for inducing an increase 
in cerebral blood flow, however future research in this 
area would benefit from a more standardized and repro-
ducible approach, particularly if the purpose is a simple 
measure of cerebrovascular response amplitude. Inhala-
tion of  CO2-enriched gas is an easily implemented and 
standardizable method, with fewer contraindications 
than rebreathing and breath-holding. While computer-
controlled  etCO2 prospective targeting is the most clini-
cally standardizable technique, it requires expensive 
equipment which is not readily available in most research 
facilities. At a minimum, researchers should take care to 
provide sufficient information regarding vascular chal-
lenge techniques so that comparisons may be made 
between studies.
Variations in imaging protocol
ASL, BOLD and DSC imaging methods are all consid-
ered valid for measurement of CVR, yet the results from 
these are not directly comparable. While MR imaging has 
a clear advantage of spatial specificity over ultrasound 
and CT-based methods, all three methods present pos-
sible drawbacks in regard to measuring CVR. BOLD, the 
most commonly used method, acquires images via the 
complex combination of blood volume, flow and oxy-
genation metabolism in the brain and thus is affected 
by subtle variations in any of these parameters, despite 
not directly measuring blood flow per se. BOLD is also 
known to be more sensitive to the baseline level of vas-
cular tension than perfusion MRI [59]. ASL, while being 
more physiologically precise, has limited spatial coverage, 
lower signal to noise ratio, and is generally considered 
less sensitive for measures of CVR [33]. As BOLD is more 
commonly used and also more accessible on conventional 
MRI scanners, it is the currently preferred sequence for 
CVR measurements, although rapid development of new 
ASL pulse sequences enabling global brain coverage may 
render it the favored method in the future. Both ASL and 
BOLD MRI have been widely used in studies of hemo-
dynamic function and cognitive performance in both 
healthy [60, 61] and patient samples [62, 63]. DSC is less 
commonly employed in CVR measurement studies, most 
likely due to the necessity of an injection of an exogenous 
contrast agent. Both BOLD and ASL are non-invasive, 
well tolerated and easily repeatable, thus either of these 
methods are considered preferable over DSC MRI for 
measurement of CVR in research studies.
Conclusion
The connections observed between hemodynamic dys-
function and cognitive impairment observed in the 
majority of these studies warrants further investigation. 
Those affected by cognitive impairment were more likely 
to exhibit decreased CVR compared to healthy controls, 
as were individuals with greater cardiovascular risk fac-
tors. Previous research using alternative methods have 
given strong indication of the causal relationship between 
dysfunctional CVR and cognitive deterioration. Given 
that vascular risk factors are often modifiable, develop-
ment of vaso-protective therapies may prevent or slow 
the progression of cognitive decline.
Due to the fact that there is still so much to investi-
gate regarding which type of vasoactive modulation and 
imaging protocol provides the richest set of data to assess 
vascular function, recommendations for measurement of 
CVR response amplitude include the inhalation of a set 
concentration of  CO2-enriched gas, in combination with 
either ASL or BOLD MRI, provided that the whole brain 
is imaged. Future research should also employ more 
comprehensive neuropsychological examination to fur-
ther unravel the nature of the association between cer-
ebrovascular reactivity and cognition.
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